Theranostic PET/CT Mobile Unit | Siemens Biograph Horizon Trailer | Image One

Chris Filut — Fri, 27 Feb 2026 15:29:08 +0000

Theranostic PET/CT: Bringing Precision Oncology on the Road

Cancer care is evolving. It is no longer just about finding disease. It is about understanding it at a molecular level and delivering therapy that is tailored to each individual patient. That is the promise of Theranostics.

Now, that promise is mobile.

The Siemens Biograph Horizon Trailer, featured in our latest video, represents a new generation of Theranostic PET/CT imaging and urology treatment solutions. It combines advanced molecular imaging with the flexibility of a fully transportable unit, expanding access to precision oncology wherever it is needed.

What Makes Theranostic PET/CT Different?

Traditional imaging identifies anatomy. Theranostic PET/CT goes further. It reveals how cancer behaves at the cellular level.

This dual capability allows physicians to:

Detect cancer earlier with high-resolution molecular imaging
Identify specific tumor receptors
Select targeted radiopharmaceutical therapies
Monitor treatment effectiveness in real time

Instead of a one-size-fits-all approach, Theranostics creates a diagnostic and therapeutic pathway built around the individual patient.

he Siemens Biograph Horizon Advantage

The Siemens Biograph Horizon PET/CT system is engineered for clarity, efficiency, and performance. Integrated into a custom mobile trailer platform, it delivers hospital-grade imaging in a transportable format.

Key advantages include:

High-sensitivity PET detection for accurate lesion visualization
Advanced CT technology for detailed anatomical correlation
Optimized workflow for oncology and urology applications
Compact, mobile design without sacrificing performance

This system is particularly impactful in Theranostic urology applications, including prostate cancer imaging and targeted radionuclide therapy planning.

Mobility Meets Precision

Access to advanced imaging can be limited by geography, infrastructure, or capital constraints. A mobile Theranostic PET/CT trailer removes those barriers.

Hospitals and cancer centers can:

Expand imaging capacity without building new facilities
Provide advanced PET/CT services in underserved regions
Support clinical trials and specialty oncology programs
Reduce patient travel burden

It is precision medicine delivered where patients need it most.

Supporting the Future of Personalized Cancer Care

Theranostics represents one of the fastest growing areas in oncology. As radiopharmaceutical therapies continue to expand, imaging must evolve alongside them.

The Siemens Biograph Horizon Trailer supports this shift by providing:

Diagnostic imaging to identify eligible patients
Quantitative data to guide therapy selection
Ongoing monitoring to assess treatment response

It closes the loop between diagnosis and therapy, forming a seamless continuum of care.

Watch the Theranostic PET/CT in Action

Our latest video showcases the Siemens Biograph Horizon Trailer and highlights how this mobile Theranostic unit is redefining cancer imaging and treatment delivery.

Explore how advanced molecular imaging and mobility come together to support personalized oncology programs across the country.

About Image One

Image One delivers innovative mobile and modular imaging solutions designed to meet the evolving needs of healthcare providers. From PET/CT to specialized Theranostic applications, we help facilities expand access, increase flexibility, and deliver advanced patient care with confidence.

What Is Theranostics? The Future of Personalized Cancer Care

Chris Filut — Fri, 30 May 2025 14:07:38 +0000

Introduction
Cancer treatment is entering a new era—one where doctors no longer rely solely on trial-and-error methods but instead harness highly targeted, personalized therapies. At the center of this transformation is theranostics—a powerful fusion of diagnostics and therapeutics that allows clinicians to visualize a tumor, treat it, and monitor progress all with the same molecular tools.

But what exactly is theranostics, and why is it becoming so central to the future of cancer care?

What Does Theranostics Mean?
The word “theranostics” comes from a blend of “therapeutics” and “diagnostics.” It refers to a medical approach that combines targeted diagnostic imaging and treatment using the same molecule or molecular family. The goal? Deliver precise treatment while reducing unnecessary side effects and costs.

For example, if a tumor expresses a certain protein (like PSMA in prostate cancer), doctors can use a radiolabeled molecule to both locate and destroy cancer cells, tailored specifically to that individual.

—

How Does Theranostics Work?
Theranostics involves a two-step process:

1. Diagnosis
Patients are first given a radioactive tracer that binds to cancer-specific markers. Using PET or SPECT imaging, doctors identify where the cancer is located and how aggressive it may be.

2. Treatment
The same molecule is then labeled with a therapeutic isotope, such as Lutetium-177 or Actinium-225. This allows targeted radiation therapy—directly to cancer cells, sparing healthy tissue.

Think of it as a guided missile: theranostics ensures the payload (radiation or drug) hits only the intended target.

Real-World Example: PSMA Theranostics for Prostate Cancer
Prostate-Specific Membrane Antigen (PSMA) is a protein found in high levels in prostate cancer cells. Doctors use Gallium-68 labeled PSMA for PET scans to locate tumors. If the scan confirms PSMA expression, the patient becomes eligible for Lutetium-177-PSMA therapy, which directly targets and destroys cancerous tissue with minimal side effects.

This approach has shown dramatic results in advanced prostate cancer, even when traditional therapies fail.

—

Benefits of Theranostics in Cancer Treatment

Precision: Targets cancer at the molecular level
Fewer Side Effects: Spares healthy tissue
Real-Time Feedback: Imaging shows whether treatment is working
Cost-Efficient: Reduces unnecessary procedures or toxic therapies
Better Outcomes: Especially for hard-to-treat or late-stage cancers

The Future of Theranostics
Theranostics isn’t limited to prostate cancer. Researchers are actively developing theranostic agents for:

Neuroendocrine tumors (NETs)
Pancreatic and brain cancers
Breast and lung cancers
Infectious diseases
Cardiovascular conditions (e.g., vulnerable plaque imaging)

Next-gen theranostics also includes nanotheranostics—tiny nanoparticles that can both deliver drugs and track their effects in real time. Artificial intelligence is also beginning to play a role, helping personalize therapy plans based on patient data and scan results.

—

Conclusion
Theranostics is more than just a buzzword—it’s a revolutionary leap toward precision medicine. As the technology advances and access improves, we’re entering a new era of personalized cancer care that is more effective, efficient, and humane.

Want to learn how theranostics could benefit your organization or patients? Get in touch with our team of experts or explore our clinical offerings today.

CTA Options (choose one or combine):

Contact us for a theranostics consultation
Download our free whitepaper: “Theranostics in 2025: What You Need to Know”
Subscribe for updates on cutting-edge oncology solutions

Theranostics – Image One Group